Full history for every metric is available with a Kvantra account
Ultimovacs ASA (ULTI.OL)
Key financial summary
Financials in NOK| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | NOK m | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | NOK m | -216 | -225 | |||||
| Net profit | NOK m | -54 | -56 | -117 | -167 | -147 | -189 | -207 |
| EPS reported | NOK | -5.50 | -8.84 | |||||
| Operating cashflow per share | NOK | -5.52 | -4.75 | |||||
| Capex per share | NOK | 0.00 | 0.00 | |||||
| FCF per share | NOK | -5.52 | -4.75 | |||||
| Free cash flow | NOK m | -190 | -154 | |||||
| Net debt | NOK m | -267 | -135 | |||||
| Book value equity | NOK m | 279 | 127 | |||||
| Book value per share | NOK | 8.12 | 16.39 | |||||
| Number of shares | m | 34.4 | 7.75 | |||||
| DPS (TTM paid) | NOK | 0.00 | 0.00 |
Financial summary
Financials in NOK| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 15.12 | 0.56 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -22.25 | -0.46 | |||||
| EV/EBITDA LTM | x | -18.44 | 0.30 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -4.48% | -268.36% | |||||
| FCF Yield | % | -4.49% | -217.66% | |||||
| Quality | ||||||||
| ROE | % | -67.73% | -104.53% | |||||
| ROIC | % | -73.19% | -250.14% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -51.13 | -101.67 | |||||
| Net Debt/EBITDA | x | 1.22 | 0.49 | |||||
| EBIT/Net interest | x | -564.75 | -564.75 | |||||
| Net debt/market cap | % | -6.31% | -191.85% | |||||
| Net debt/Equity | x | -0.95 | -1.07 | |||||
| Gross debt/equity | x | 0.01 | 0.01 | |||||
Company overview
Ultimovacs ASA is a pharmaceutical company based in Oslo, Norway, established in 2011. The firm specializes in developing immunotherapies to combat various cancers. Its main product in development is UV1, a peptide vaccine engineered to stimulate a T-cell immune response against telomerase, an antigen found widely across different cancer types.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Ultimovacs ASA (ULTI.OL)
Ultimovacs ASA is a pharmaceutical company based in Oslo, Norway, established in 2011. The firm specializes in developing immunotherapies to combat various cancers. Its main product in development is UV1, a peptide vaccine engineered to stimulate a T-cell immune response against telomerase, an antigen found widely across different cancer types.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free